Granulocyte-colony stimulating factor use in alcohol-associated hepatitis: is it time to promote liver regeneration?

Severe alcohol-associated hepatitis (sAH) is a life-threatening condition with limited treatment options. Corticosteroids are currently recommended as the first-line therapy, but their effectiveness is controversial. Liver transplantation is an option for non-responders, but it is not widely available. A recent study published in the American Journal of Drug and Alcohol Abuse suggests that the use of granulocyte-colony stimulating factor (G-CSF) in combination with pentoxifylline or corticosteroids may be associated with lower mortality rates in sAH. However, conflicting evidence and the need for larger trials indicate that further research is necessary to determine the potential benefits and risks of G-CSF in sAH treatment. In the meantime, supportive therapies, prevention of complications, and alcohol abstinence remain crucial in managing sAH. Public health policies to reduce alcohol use and detect alcohol-related health issues early could also help prevent sAH mortality. [Extracted from the article]